오쿨리스 홀딩 AG(OCS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $10.14 (+1.60%), 시가총액 $1.82B, 52주 최저~최고 $16.13 ~ $32.65.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was for
오쿨리스 홀딩 AG의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
오쿨리스 홀딩 AG의 현재 주가는 $10.14 (+1.60%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
오쿨리스 홀딩 AG의 시가총액은 약 $1.82B입니다.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company